Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06933056 | Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs | EARLY_PHASE1 | RECRUITING | 20 | — | — | Sep 2, 2025 | Sep 1, 2026 | Sep 15, 2025 | 1 | United States |
Measured from blood samples
| Arm | Type | Description |
|---|---|---|
| Platelet function in healthy subjects administered sotagliflozin vs. antiplatelet agents | EXPERIMENTAL | Platelet responsiveness will be assessed in the blood from subjects administered sotagliflozin, aspirin, clopidogrel, or apixaban in randomized order given as a single drug administration. |
| Name | Type | Description |
|---|---|---|
| Sotagliflozin (SOTA) followed by 3 drugs in a random order | DRUG | 400 mg/day SOTA Each drug will be given daily for 2 weeks. |
| Aspirin followed by 3 drugs in a random order | DRUG | 81 mg/day Aspirin Each drug will be given daily for 2 weeks. |
| Clopidogrel followed by 3 drugs in a random order | DRUG | 75 mg/day clopidogrel Each drug will be given daily for 2 weeks. |
| Eliquis followed by 3 drugs in a random order | DRUG | 5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks. |
Inclusion Criteria: \- Exclusion Criteria: * Students under the direct supervision of Dr. Michael Holinstat * Subjects diagnosed with Type I diabetes or those with ketoacidosis * Subjects with a history of alcohol abuse, pancreatitis or pancreatic surgery, or subjects taking a ketogenic diet * Wo...